Leadership & Staff

THE BRI EXECUTIVE COMMITTEE

The BRI is led by three faculty directors and the Chief Academic Officer. As members of the BRI Executive Committee (EC), these representatives are responsible for directing the BRI and for representing the BWH research community inside and outside the institution.

Director
Ursula Kaiser, MD

Co-Director
Charles N. Serhan, PhD, DSc

Immediate Past-Director
Marc Sabatine, MD, MPH

Chief Academic Officer
Paul Anderson, MD, PhD

Executive Director
Jacqueline Slavik, PhD, MMSc

CALL FOR NOMINATIONS
for the BRI Research Oversight Committee (ROC)

The Brigham Research Institute (BRI) has opened a Call for Nominations for SIX elected members of the BRI Research Oversight Committee (ROC) to serve from November 2021-September 2023. There are junior and senior faculty positions available in basic, clinical and population science/research.  The ROC, which governs the BRI, was established to foster transparency and accountability in the decision-making process for the research enterprise and to plan new strategic initiatives. Read more about eligibility, timeline and to nominate yourself or peers by Monday September 20.  Further questions can be directed to the BRI, at bwhbri@partners.org

2021 ROC Guest Slots Available

The BRI Executive Committee is opening three guest slots at each monthly ROC meeting. If you wish to attend a ROC meeting, please sign up here (note that you may only attend one ROC meeting per calendar year as a guest). Feel free to email bwhbri@partners.org with questions.

BWH Research Oversight Committee (ROC) Membership Application

We invite BWH entities not currently represented on the ROC through another category/office to apply for membership.Please note that all ROC members are required to attend monthly meetings, review and/or vote on topics discussed and disseminate relevant information shared at these forums to their respective communities. If you would like to preview a meeting before applying for membership, please see above to sign up for a guest spot at a future ROC meeting.

The BRI Research Oversight Committee

The BRI is governed by the ROC which is made up of the BRI Executive Committee, department chairs or their representatives, BRI Center and Program Co-Chairs, elected members and various BWH/Partners leaders and ad hoc members. The ROC was established to foster transparency and accountability in the decision-making process for the research enterprise and to plan new strategic initiatives; the composition of the ROC is intended to collectively reflect the diversity of the BWH research community.
Research entities that are distinct from Hospital departments may request representation on the ROC by sending a brief statement of interest to BWHBRI@partners.org.

HOSPITAL DEPARTMENT REPRESENTATIVES

Anesthesia
James P. Rathmell, MD (Chair)
Jochen D. Muehlschlegel,  MD (Alternate)

 

Dermatology
Thomas S. Kupper, MD (Chair)
Hans Widlund, PhD (Representative)

 

Emergency Medicine
Michael J. VanRooyen, MD, MPH (Chair)

 

Medicine
Joseph Loscalzo, MD, PhD (Chair)
Nancy Berliner, MD (Representative)

 

Neurology
Tracy T. Batchelor, MD, MPH (Chair)
Francisco Quintana, PhD (Representative)

 

Neurosurgery
Ennio A. Chiocca, MD, PhD (Chair)
Nathalie Agar, PhD (Representative)

 

Newborn Medicine
Terrie E. Inder, MBCHB (Chair)
Kate Gregory, PhD, RN (Alternate)

 

Nursing
Patricia Dykes, RN, DNSc, MA

Obstetrics/Gynecology
Nawal M. Nour, MD,  MPH (Chair)
Cynthia Morton, PhD (Representative)

 

Orthopedic Surgery
James D. Kang, MD (Chair)
Julie Glowacki, PhD (Alternate)

 

 

Pathology
Jon Christopher Aster, MD, PhD (Interim Chair)
Sean R. Stowell, MD, PhD (Alternate)

 

Physical Medicine and Rehabilitation
Ross D. Zafonte, DO (Chair)

 

Psychiatry
David  A. Silbersweig, MD (Chair)
Katherine Burdick, PhD (Representative)

 

Radiation Oncology
Daphne A. Haas-Kogan, MD (Chair)
G. Mike Makrigiorgos, PhD, DABMP/DABR (Alternate)
Ross I. Berbeco, PhD (Second Alternate)

 

Radiology
Catherine S. Giess, MD
Noby Hata, PhD (Representative)

 

Surgery
Gerard M. Doherty, MD (Chair)
Steve Mentzer, MD (Representative)
James Lederer,  PhD (Alternate)

BRI CENTER CO-CHAIRS

Cancer Research Center
Jon Christopher Aster, MD, PhD

 

Cardiovascular, Diabetes & Metabolic Disorders Research Center
Mark Feinberg, MD
Marie McDonnell, MD
C. Keith Ozaki, MD

 

Connors-BRI Center for Research on Women’s Health & Gender Biology
Hadine Joffe, MD, MSc
Ursula Kaiser, MD
Kathryn Rexrode, MD

 

Genomics Center
Robert Green, MD, MPH
Calum MacRae, MD, PhD
Heidi Rehm, PhD
Christine Seidman, MD

Infectious and Immunologic Diseases Research Center
Ana Anderson, PhD
Rachael Clark, MD, PhD
Matthew K. Waldor, MD, PhD

 

Lung Research Center
Raphael Bueno, MD
Bruce Levy, MD
Edwin Kepner Silverman, MD, PhD
Raphael Bueno, MD

 

Musculoskeletal Research Center
Jeff Duryea, PhD
Nancy Ann Shadick, MD, MPH

Neurosciences Research Center
Alexandra Golby, MD
Emily Stern, MD

 

Patient Centered Comparative Effectiveness Research Center
Elliot Israel, MD
Joel Weissman, PhD

 

Regenerative Medicine Research Center
Andreas Gomoll, MD

BRI PROGRAM CO-CHAIRS

Bioinformatics

Scott Weiss, MD

Biomedical Imaging

Clare Tempany, MD

Clinical Investigation

Lindsey R. Baden, MD

Pre-Clinical Models

Daniela Dinulescu, PhD

Cynthia Lemere, PhD

Arlene Sharpe, MD, PhD

ELECTED REPRESENTATIVES

Junior Faculty
William Oldham, MD, PhD
Basic Research

Elizabeth Janiak, ScD
Population Science

Katherine Gregory, PhD
Clinical Research 

Senior Faculty
Jing Zhou, MD, PhD
Basic Research

Howard D. Sesso, SCD, MPH
Population Science

Postdoctoral Fellows

Ashley Ogawa-Wong, PhD

Yashini Govender, PhD (May 2019)

First alternate: Stephania Libreros Ruiz, PhD

Second alternate: Deepak Bhere, PhD

Additional Members

Interim President and Chief Medical Officer, Brigham and Women’s Hospital
Sunil Eappen, MD, MBA

 

Harvard Catalyst Representative
Elliot Antman, MD

 

Development

  • Susan Rapple, Chief Development Officer
  • Kristin Garrity, Associate Vice President, Development, Brigham and Women’s Hospital
  • Linda Jones, Associate Vice President for Institutional Giving

 

Senior Science Communication Specialist
Haley Bridger
Chief Academic Officer, Mass General Brigham
Ravi I. Thadhani, MD, MPH
Vice President, Clinical Trials Research and Administration, Mass General Brigham
Stephen D. Wiviott, MD, FACC

 

People/Career/Development/Alumni

  • Thomas Michel, PhD
  • CIMIT Site Miner, BWH
  • Frederick Schoen, MD, PhD

 

Partners Innovation

  • Christopher Coburn, Chief Innovation Officer, Mass General Brigham
  • Glenn Miller, PhD

 

Digital Innovation Hub and Chief Information Officer
Adam Landman, MD, MS, MIS, MHS

 

Partners Research Management
Andrew Chase

 

Research Administration and Compliance
Allison Moriarty, MPH

 

Brigham Education Institute
Erik K. Alexander, MD, FACP

Scientific Advisory Board
  • James Bradner, MD President Novartis Institutes for BioMedical Research (NIBR), Novartis
  • Gerald Chan, PhD Founder, Morningside Group Ltd.
  • Susan Hockfield, PhD President Emerita and Professor of Neuroscience, Massachusetts Institute of Technology (MIT)
  • Jeff Leiden, MD, PhD Executive Chairman, Vertex Pharmaceuticals
  • Terry McGuire, MBA, MS Co-Founder and General Partner Polaris
  • Geoff Smith, JD  Professor of Biology; Core Member, Broad Institute; Investigator, Howard Hughes Medical Institute
  • Michael Rosenblatt, MD Chief Medical Officer, Flagship Ventures
  • Geoff Smith, JD Managing Partner, Digitalis Ventures
  • Elias Zerhouni, MD President, Global Research & Development, Sanofi

The BRI Administrative Staff

JACQUELINE M. SLAVIK, PHD, MMSC
EXECUTIVE DIRECTOR, BRIGHAM RESEARCH INSTITUTE

Dr. Jacqueline M. Slavik is the executive director of the Brigham Research Institute (BRI) at Brigham and Women’s Hospital. In this role she shapes and implements the BRI’s overarching mission to accelerate discoveries that improve human health by fostering groundbreaking, interdepartmental, and interdisciplinary research, ranging from basic fundamental studies to clinical innovations.  She manages a team who works to provide a clear voice for the entire BWH research community, raise the profile of research at BWH, develop mission-centric collaborations with external entities and engage the scientific community in fundraising. Dr. Slavik received her PhD in Immunology from Harvard University, a Master of Medical Science from Harvard University and a BS in Biology from State University of New York at Albany. Dr. Slavik did her postdoctoral fellowship in the Center for Neurologic Diseases in the Department of Neurology at BWH, and held a faculty appointment as instructor in Neurology at Harvard Medical School prior to transitioning to the role of senior program manager at the BRI, from which she moved into her current leadership role. Her research interests include T lymphocytes and T lymphocyte signaling and their involvement in cancer and autoimmune diseases such as multiple sclerosis.

ANU SWAMINATHAN, PHD
DIRECTOR, SCIENTIFIC PROGRAMS & PARTNERSHIPS

Dr. Anu Swaminathan serves as the Director for Scientific Programs and Partnerships at the Brigham Research Institute (BRI). In this role, she drives a broad range of activities related to the BRI’s multiple research centers, programs and other pan-institute initiatives with the ultimate goals of increasing the visibility of the exciting research happening at BWH and catalyzing fundraising for the same in order to fuel the discovery and innovation engine of the hospital. As part of this mandate, she leads efforts to establish new research collaborations within BWH as well as with external entities including industry; diversify the funding portfolio of researchers and clinician scientists and; foster institutional involvement and community building within the hospital’s research fraternity. Anu has a PhD in Biochemistry from the University of Connecticut and brings an eclectic blend of professional experiences spanning basic research, technology commercialization, policy making and administration to her current role.

TREY TOOMBS, PHD
SENIOR PROGRAM MANAGER

Dr. James (Trey) Toombs is the Program Manager for the Brigham Research Institute (BRI) where he manages the activities of the research centers and programs sponsored by the BRI. In this role, Dr. Toombs works closely with center and program leaders to develop and execute initiatives to raise the visibility of the research being conducted at BWH and foster new interdisciplinary and interdepartmental research programs. Prior to joining the BRI, Dr. Toombs was a research fellow at Massachusetts General Hospital where he employed NextGen sequencing technologies to probe the role of a germline-specific class of small non-coding RNAs (piRNAs) in regulating the maternal transcriptome in Xenopus oocytes. Prior to that, he received his PhD in Biochemistry and Molecular Biology from Colorado State University where he performed a mutational analysis to identify the molecular determinants of prion formation in yeast and developed a robust algorithm capable of both predicting the prion forming propensities of known proteins and rationally designing new prion forming proteins de novo. Dr. Toombs brings the analytical and problem solving skills he developed during his years as a research trainee to his current role of managing the research centers and programs at the BRI.

ALEXANDRA GALLANT
WEB MEDIA MANAGER & CREATIVE DESIGNER

Alexandra Gallant is the Web Media Manager & Creative Designer at the Brigham Research Institute. Her role is focused on identifying ways to use visual communication tools to support the efforts of the research community.  With an emphasis on user experience and design standards,  she provides creative direction for all BRI initiatives, including the development of research web sites, email communication  vehicles and print collateral.  She studied Criminal Justice and English at Northeastern University. She is also an accomplished artist and illustrator.

AMANDA KOMAROWSKI
WEB DESIGNER

Amanda Komarowski is a Web Designer at the Brigham Research Institute. She manages the operations for the development of new research websites for laboratories and research groups, and assists with a range of online communication efforts directed at both internal and external audiences. Amanda graduated from Bridgewater State University in 2010, with a degree in Graphic Design & Communication Studies.

SARA YOHANNES
PROGRAM COORDINATOR

Sara Yohannes is the Program Coordinator at the Brigham Research Institute (BRI). She came to us from the Brigham and Women’s Orthopedic and Arthritis Center in August of 2014, before that she worked at AIDS Action Committee of Massachusetts. Sara graduated from Suffolk University with a Bachelor of Science in Business Administration in 2012.

MARIANNA JAKAB, MSC
WEB DEVELOPER & DESIGNER
ANNA DE CRISTOFARO
ADNINISTRATIVE ASSISTANT
GLORIA BRAND, MPA
SENIOR PROGRAM MANAGER
FRANK S. DAVID, MD, PHD
INNOVATION STRATEGIST

Dr. David serves as Innovation Strategist at the BRI, in addition to being Founder and Managing Director of Pharmagellan, a Boston-area biotech consulting firm. After studying molecular biophysics and biochemistry at Yale, Dr. David received his M.D. and Ph.D. degrees from Columbia University’s College of Physicians and Surgeons. Dr. David completed his clinical training in anatomic pathology at Brigham and Women’s Hospital, and then served as Instructor in Pathology at Harvard Medical School and Brigham and Women’s, where he researched cell signaling in cancer and kidney development. As Director in the consulting arm of Leerink Partners, a leading healthcare investment bank, Dr. David led advisory engagements for corporate, commercial, R&D, business development, and investor clients across all major therapeutic areas and business sectors, including biopharma, devices, diagnostics, life sciences tools, and healthcare services. He also co-founded Leerink’s Transactional Consulting practice, which advised financial and strategic investors and early-stage companies side-by-side with Leerink’s investment banking team. Dr. David also served as Director of Strategy in AstraZeneca’s Oncology Innovative Medicines unit, where he led business strategy efforts from target identification through Phase 2a, spearheaded initiatives in end-to-end franchise strategy and portfolio valuation, led external communications focused on R&D collaborators and investors, and provided commercial support to pipeline projects and in-licensing teams.   Dr. David writes about biomedical innovation at Forbes.com and the Pharmagellan blog, and maintains an active presence on Twitter (@Frank_S_David).

X